PIN52 Cost Associated with Adverse Events and Health Care Resources Utilization in Hepatitis C Virus Infection in Quebec, Canada  by Lachaine, J. et al.
 VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  A349
transformed to common logarithms. Costs are stated in € (1€ = 25.5CZK). Results: 
A total 100 patients (about 10-15% of all HIV treated in the Czech Republic) were 
included. The mean age was 41.9 years (range 23-71), time since diagnosis 5.8 years 
(range 1-26), and period of assessment 30.5 months. Average total annual costs were 
highest for CD4+ <200 (22,905€ ; p<0.05) vs. CD4+ 200-499 (17,801€ ) and CD4+ >500 
(17,043€ ). HIV medication accounted for the majority of costs in all three subgroups 
(range 62% in CD4+ <200 to 88% in CD4+ >500). Patients with a disease duration of 
>10 years had highest annual costs of 22,841€ (p<0.05) compared to 15,783€ (dura-
tion 5-10 years) and 16,777€ (<5 years). HIV-medication accounted for the majority 
of costs here as well (from 70% to 88%; NS). In this analysis 17 % of costs in patients 
with disease duration of >10 years were due to hospitalization vs. 5 % in both other 
groups (NS). ConClusions: Similarly to published literature, we found highest 
costs in patients with low CD4+ lymphocytes and longer disease duration.
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objeCtives: Clostridium difficileinfection (CDI) is the leading cause of infectious 
diarrhoea in hospitalised patients. The majority of published burden of CDI stud-
ies refer to US or northern European populations. Knowledge of the burden of CDI 
on health care resource utilisation in Spain is limited. The aim of the study was to 
provide recent data on the burden of CDI in terms of hospital resources and costs 
and in particular attributable length of stay. Methods: A retrospective study was 
carried at a leading teaching hospital in Madrid. Data refer to sequential cases of 
CDI during the year 2011. Data were extracted from patient records using a prede-
fined structured protocol. Hospital onset CDI cases were matched at a ratio of two 
non-infected patients for each case to adjust for confounding variables. Results: 
A total of 44 CDI cases were identified of whom 25 were health care-associated 
and hospital-onset. The mean duration of diarrhoea (days) was 10.12+7.98. Using 
median regression, the attributable length of stay (LOS) due to CDI was 9.98+2.21 
days. The average number of isolation days was 9.21+8.27. The majority of patients 
were treated with oral metronidazole. The first episode cure rate was 83.7%, 30-day 
and overall mortality were 18.6 and 25.6% respectively, attributable mortality was 
4.65%. A total of 9.3% of patients experienced a recurrence occurring within 2-8 
weeks within hospital stay. The cost attributable to an individual case of CDI would 
be 4,331 euros, of which over 90% is associated with hospital LOS. ConClusions: 
Our results highlight the significant burden of CDI in a large Spanish hospital. These 
costs will only continue to rise as the incidence of CDI continues to increase. A major 
breakthrough in cost reduction of CDI would be an intervention or procedure that 
shortens hospital length of stay and/or reduces episode recurrence.
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objeCtives: Decreased susceptibility to vancomycin has led to recommendations for 
increased serum concentration targets for some infections, which has been shown 
to increase the risk of nephrotoxicity (NT). The objective of this study was to deter-
mine if vancomycin-induced nephrotoxicity has a significant impact on cost from the 
hospital perspective or on length of stay. Methods: A cost of illness study from the 
hospital perspective. We conducted a secondary analysis of a cohort of 398 randomly 
selected inpatients receiving vancomycin in a tertiary care hospital in Rochester, New 
York, USA. Total and variable costs were generated by hospital accountants using 
micro-costing methods. NT was defined as 0.5 or 50% or greater increase in serum 
creatinine from baseline. Generalized linear models with log link and gamma distribu-
tion and semi-log regression were used to model total and variable costs and length 
of stay, respectively. Cost estimates are reported in 2009 USD. Results: Forty-nine 
(12%) of patients had NT. The unadjusted median variable costs for patients with NT 
were higher than for patients without NT ($47,511 vs. $22,355, p< .0001). On multi-
variable analysis, variable costs were 18% greater for patients with NT compared to 
patients without, but this difference was not statistically significant. The median 
length of stay for patients with NT was two-fold greater than for patients without 
NT (22 vs. 11 days, unadjusted, p< .0001). After accounting for severity of illness 
and other factors, NT patients stayed on average 46% longer than non-nephrotoxic 
patients. ConClusions: Patients with NT have significantly increased length of 
stay relative to patients without NT. Further research is needed to confirm whether 
increased length of stay has a meaningful impact on costs. As vancomycin suscep-
tibility continues to decrease, higher doses of vancomycin may lead to an increased 
incidence of NT and an increase in resource utilization among these patients.
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objeCtives: The purpose of this study was to estimate the health care resource uti-
lization, more specifically resource utilization for management of the most common 
adverse events (AE) associated with current treatment of hepatitis C virus (HCV) infec-
tion, in a real life setting. Methods: A retrospective study of the Quebec provincial 
drug reimbursement program (RAMQ) was conducted using a random sample of 
patients who filed at least one script for an HCV medication (pegylated-interferon and 
ribavirin (Peg-Riba) +/-boceprevir or telaprevir) between January 2007 and December 
2012. Data on medical (excluding nurse visits) and pharmaceutical services were 
extracted from the RAMQ database. We report health care resources used during 
HCV treatment including outpatient physician’s visits and procedures, emergency 
inclusion criteria, and 42% were adherent. After adjusting for confounders, ART adher-
ence was associated with 29% and 31% reductions in non-pharmacy costs (p< 0.0001)), 
67% and 80% increases in total pharmacy costs (p< 0.0001), 43% and 49% reductions 
in hospitalizations (p< 0.0001), and 41% and 26% reductions in emergency depart-
ment visits (p< 0.0001), among commercially insured and Medicaid patients, respec-
tively. ConClusions: This study suggests that ART adherence among commercially 
insured and Medicaid HIV patients in the US may be suboptimal, and that adherence 
is associated with improved economic outcomes among these patients.
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objeCtives: To perform a systematic literature review of economic evidence for 
genotype 1 hepatitis C virus (HCV) treatments. Methods: Searches were per-
formed in MEDLINE, MEDLINE In-Process, EconLit, Embase, BIOSIS, and the Cochrane 
Library, to identify economic evaluations, cost/resource studies, and utility studies 
in patients with genotype 1 HCV. Searches were limited to articles published since 
2000. Additional searches were performed on the ISPOR conference and key Health 
Technology Assessment (HTA) websites. Results: The review identified 53 economic 
evaluations, 17 HTA documents, 57 cost/resource use studies, and 19 utility stud-
ies. The majority of economic evaluations were in interferon-containing regimens 
and were performed using lifetime horizon Markov models. Incremental cost-effec-
tiveness ratios ranged from $4,570.31 to $157,404.13, depending on patient severity, 
the treatment used and the duration of treatment. Boceprevir and telaprevir triple 
therapies were shown to be cost-effective compared with peginterferon and ribavirin 
alone. In the cost studies, total all-cause, annual costs for patients with HCV ranged 
from $3,236 to $85,081, depending on the patients’ disease status and whether they 
were currently receiving treatment. Indirect costs for HCV patients were reported less 
frequently, but they ranged from $1,424 to $10,316 per patient per year. Utilities for 
patients with HCV ranged from 0.24 for patients experiencing severe adverse events 
to 0.89 for patients in sustained virological response. Recent economic models tended 
to use utility data taken from previous models or HTA submissions. ConClusions: 
Numerous recent cost-effectiveness studies are available for HCV; however, many 
of the economic evaluations are based on previous models. There is a particular 
scarcity of updated country-specific utility data. As more treatment options become 
available, and more robust models are developed, enhanced utility and cost studies 
may be needed.
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objeCtives: Meningococcal disease (MD) is a rare, life-threatening infection most 
common in infants (age < 1 year), adolescents, and persons living in close quar-
ters. In this study, we documented trends in hospital costs, length of stay (LOS), 
and mortality associated with pediatric MD cases in the United States (US) from 
2000 to 2009. Methods: Data for pediatric (age ≤ 20 years) MD-related hospitaliza-
tions (discharges with ICD-9-CM 036.xx) from the 2000, 2003, 2006, and 2009 HCUP 
Kids’ Inpatient Databases (KID) were retrospectively analyzed. Charges were con-
verted to costs using a 0.5 cost-to-charge ratio. Weighted, nationally representa-
tive estimates of costs per admission (in 2012 US dollars), LOS, and case fatality 
rates were descriptively analyzed for each year. Results: By year, total (weighted) 
numbers of pediatric MD-related hospitalizations in the US were: 2000 (N= 1,680), 
2003 (N= 1,089), 2006 (N= 745), 2009 (N= 581). Mean [SD] LOS for these hospitaliza-
tions was 8.4 [12.9] days in 2000, which decreased modestly to 7.7 [9.6] and 7.9 
[8.3] days in 2003 and 2006, respectively, before a substantial increase to 9.3 [13.9] 
days in 2009. Mean [SD] cost per admission fluctuated accordingly, increasing from 
$25,739 [$60,929] in 2000 to $33,530 [$62,499] in 2009. Case fatality rates, however, 
remained relatively unchanged during the period, declining slightly from 4.7% in 
2000 to 4.3% in 2009, although a noticeable spike occurred in 2003 when 5.8% of 
cases died. ConClusions: MD in the US pediatric population is associated with 
high costs resulting from hospital stays that typical exceed 1 week. Our estimated 
case fatality rate (~5%), while high, is lower than the 10-15% fatality rate estimated 
by the US Centers for Disease Control, which includes estimates from all age groups 
combined (pediatrics and adults). In light of these findings, recent efforts to raise 
awareness of MD as a serious public health concern should be continued.
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objeCtives: To assess direct medical costs of HIV patients, based on CD4+ lym-
phocyte count and duration since diagnosis in the Czech setting. Methods: We 
analyzed retrospectively costs of HIV patients in a single center. The analyzed sam-
ple included patients with a disease history of 12 month and longer, who regularly 
visited the center. Resource use, derived from the hospital information system, 
included services delivered at the HIV center and other hospital wards. The ret-
rospective period covered up to 36 months; average annual costs were calculated. 
Resource use was analyzed separately for (a) groups of CD4+ count (<200; 200-499; 
≥ 500); (b) time since diagnosis (<5 years; 5-10 years; >10 years). For comparison, 
two-sided Student’s t-test was used; to achieve normal distribution, values were 
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objeCtives: Most industrialized countries strive to guarantee long term sustainabil-
ity for HIV antiretroviral treatment . By assessing the most relevant current predictors 
of costs of antiretrovirals(HAART) might represent the first step to understand spend-
ing drivers and to plan cost reduction strategies. Methods: A retrospective sample 
of HIV outpatients followed at 5 Italian Hospitals in 2012 was collected. Demographic 
features, current HIV viral load, current and Nadir CD4 T-celI counts, time from HIV 
diagnosis, AIDS-defining events, HAART line and HCV coinfection were taken into 
consideration. Individual ARV regimen-costs were based on local pharmacy data-
sets from December, 2011, and log-transformed in the final multivariate models. 
Univariate analyses were performed to identify potential predictors and stepwise 
multivariate regressions were used to identify independent predictors of higher indi-
vidual costs, using Stata 10.1 package. Results: We included 2044 patients, 69.0% 
males, mean age 47.2±10.0 years; 33.4% HCV-coinfected, mean time from HIV diag-
nosis 13.3±7.9 years, mean nadir CD4 T cell counts 239±169.3 cell/mm3; mean current 
CD4T-cell counts 590±302.6 cell/mm3, 30.8% AIDS classified. Patients on HAART were 
1,902 (93.0%),among treated patients, 19.0% presented an HIV-viremia> 50 c/mL. Mean 
annual individual HAART-costs were € 9,376±3,501 (782-29,852). At univariate analysis, 
a significant association was found between costs and age time from HIV diagno-
sis, previous AIDS diagnosis, HCV-coinfection current and Nadir CD4T-cell counts, 
HAART-line, HIV-viremia and site of care. In the final regression model, HAART costs 
showed independent and direct correlation with HAART lines (p< 0.001), detectable 
viremia (p< 0.001) and time from HIV diagnosis (p= 0.009); inverse correlation with 
Nadir CD4 T-cell counts (p= 0.01). Being treated at 2 of 5 centre was another predictor of 
higher costs.(P< 0.001). ConClusions: Higher HAART-costs were strongly associated 
with previous treatment failures and detectable HIV-viremia; a more compromised 
immune status at clinical presentation and a longer duration of HIV infection showed 
independent contribution, focusing on timely diagnosis of HIV infection.
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objeCtives: Develop model simulating economic implications of alternative treat-
ment strategies for acute bacterial skin and skin structure infections (ABSSSIs) 
with suspected Methicillin-Resistant Staphylococcus aureus (MRSA) that consid-
ers antibiotic switches, course duration, route of administration and location of 
care (LOC). Methods: Discrete event simulation (DES) tracks patient pathways 
through various LOC (ED, inpatient, outpatient) during ABSSSI treatment for sus-
pected MRSA. Model assumes 60% of patients hospitalized. Multiple pathways are 
allowed: patients responding can move to outpatient to finish treatment, switch 
treatment at discharge or receive 2nd line treatment if not responding. Patients 
accrue resource use, time in LOC and costs. Hospital days obtained from analysis 
of Premier Hospital Database. Three cohorts created; all assigned to receive van-
comycin (VAN) 1st line therapy. Upon discharge, one cohort continued on VAN, one 
switched to oral linezolid (LIN), one to daptomycin (DAP) to complete treatment. 
Costs are from the Medicare perspective in 2012 USD. Results: Hospital plus out-
patient days range from 11.1 (VAN) to 14.5 (LIN); costs ranged from $6,983 (LIN) 
to $8,122 (VAN) with suspected MRSA. By comparison, reatment duration ranged 
from 9.97 (VAN) to 13.02 (LIN) and total costs ranged from $6,889 (LIN) to $9,354 
(VAN) when MRSA is not always suspected. Despite longer LIN treatment, costs are 
lower because of avoided infusion costs. Outpatient costs account for 22% (LIN) to 
33% (VAN) of total costs. Sensitivity analysis examined impact on cost when treat-
ment duration varied per drug labeling. Total costs varied from $6,756 to $7,158 
when duration of LIN ranges from 8 days to 12 days. ConClusions: Treatment 
choice and LOC have major impact on ABSSSI resource use and costs. Suspected 
MRSA increases treatment duration and cost. Economic implications for payers and 
providers should be evaluated using models that capture these elements in view 
of long-acting lipoglycopeptide IV antibiotics in development that avoid repeated 
infusions and may allow for less inpatient treatment.
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objeCtives: Adverse events (AEs) and premature treatment discontinuation of pro-
tease inhibitor (PI) therapy in the treatment of chronic hepatitis C (CHC) may mitigate 
the benefits of improved sustained virologic response. We use data from a recent study 
to estimate the economic impact of PI therapy in the cirrhotic non-responder popula-
tion. Methods: In the Compassionate Use of Protease Inhibitors in viral C cirrhosis 
(CUPIC) study, patients with compensated cirrhosis and genotype 1 CHC were treated 
with boceprevir (n= 205) or telaprevir (n= 292) in combination with peginterferon alpha 
and ribavirin. The investigators reported safety and tolerability in an interim 16-week 
analysis. Using CUPIC data and micro-costing technique, we estimate the costs of treat-
ment-related hematologic and rash AEs by severity (Grades 2-4) and the cost of drug 
wastage using PI discontinuation rates due to serious AEs (SAEs) (7.3% boceprevir; 14.7% 
telaprevir). We surveyed 3 hepatologists to ascertain treatment patterns related to AEs 
and combined these estimates with cost data to compute mean costs per treatment 
group from the US payer perspective during the first 16 weeks of therapy. Results: The 
AE-related costs were $1,980 and $2,161 for telaprevir and boceprevir treated patients, 
respectively, for the first 28 days of treatment. Medication-related costs of premature 
discontinuation due to SAEs were estimated at $8,463 for telaprevir and $1,575 for 
visits, hospitalization days and costs associated with adverse events, which included 
medical services and medications. Results: The study included 1,081 patients who 
used at least one HCV medication (mean age of 46.4 years [SD= 10.7], 64.8% men). 
Peg-Riba only, Peg-Riba+boceprevir and Peg-Riba+telaprevir was used by 1,029 (95.2%), 
50 (4.6%) and 18 (1.7%) patients respectively. Fifty-seven patients (5.3%) required a 
subsequent HCV treatment during the study period. The mean duration of treatments 
was 30.4 weeks (SD= 16.1). During HCV treatment, the average number of health care 
resources per patient was 13.2 physician’s visits and procedures, 1.0 hospitalization 
day and 0.9 emergency visit. While receiving HCV treatment, 191 (17.7%) of patients 
required erythropoietin, 353 (32.7%) received rash treatments and 541 (50.0%) were 
treated for depression. Estimated costs associated with management of these three 
AE were CDN$10,834, CDN$78 and CDN$268 per patient respectively. ConClusions: 
HCV treatment is associated with significant health care resource utilization. A high 
proportion of patients experienced AE for which management was associated with 
substantial additional costs, especially the anemia treatment. Thus, the cost of AE 
should be considered in future treatment options.
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objeCtives: Genital warts (GW), 90% of which are caused by human papillomavirus 
(HPV) types 6 and 11, are a significant problem in the UK. The cost of managing GW 
in 2010 was previously estimated at £52.4 million. The objective of this study was 
to estimate the cost of GW management up to 2012, and to determine the cost by 
UK jurisdiction. Methods: Population statistics were obtained from the Office of 
National Statistics for the UK, England and Wales; the General Register Office and 
2011 census data for Scotland; and the Northern Ireland (NI) Statistics and Research 
Agency. Numbers of GW cases in genito-urinary medicine (GUM) clinics were 
obtained from the Health Protection Agency for the UK and England; the Information 
Services Division for Scotland; the Communicable Disease Surveillance Centre for 
Wales; and the Public Health Agency for NI. The number of cases treated in primary 
care was estimated from The Health Improvement Network database. Population 
statistics and GW cases were extrapolated by jurisdiction to 2012. The number of 
visits and therapy required for GW management were estimated by GUM experts 
for standard and hard-to-treat patients. Costs were obtained from the most recent 
National Health Service (NHS) Payment by Results tariffs, Personal Social Services 
Research Unit and British National Formulary. Results: The model estimated 
220,779 GW cases in the UK, costing £58.42 million annually (£265 per patient). For 
England, 157,693 cases were estimated costing £41.72 million; for Scotland 7,461 
cases costing £1.90 million; for Wales 7,091 cases costing £1.87 million; and for NI 
3,619 cases costing £0.95 million. ConClusions: The full NHS costs for the man-
agement of GW have never before been estimated separately for each jurisdiction. 
The results of the model reveal a significant economic burden which is important 
to quantify when understanding the value of quadrivalent HPV vaccination.
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objeCtives: The ANRS CO20-CUPIC study was designed to evaluate triple therapy 
(TT) efficacy and safety in HCV-cirrhosis treatment-experienced patients in the 
French Early Access Programme. A 60-week interim analysis has been reported 
confirming better clinical outcomes than double therapy in a real clinical setting. 
However, independently of the protease inhibitor (PI) used, boceprevir (BOC) or tel-
aprevir (TLV), treatment failure (TF) was reported in up to 60% of the patients. Little 
is known about these patients’ treatment cost: that of successfully treated patients 
can be generally calculated from the full course of PI treatment, but the cost of those 
who failed highly depends on TF timing. Our objective is to estimate the average PI 
cost/patient who failed treatment based on CUPIC study reported data. Methods: 
Using reported data on ITT virological response and TF, BOC and TLV on-treatment 
rates over time were estimated. Based on this curve, the average PI treatment duration 
and average PI cost/patient who failed treatment were calculated. When not enough 
information about time to treatment discontinuation was available, the same con-
servative approach was applied for both drugs, considering the midpoint of the treat-
ment interval. Sensitivity analyses on the time to TF were performed to confirm the 
robustness of the results. Results: A total of 472 patients (72%) were included in the 
60-week interim analysis. Independently of the IP used, about 60% the patients who 
start treatment did not achieve viral cure and their estimated average PI treatment 
duration was 26 wks in BOC patients and 11 wks in TLV patients. The average PI cost/
patient who failed treatment with TLV (23.012€ ) was 26% higher than that of treatment 
with BOC (18.253€ ). The sensitivity analysis confirmed the robustness of the base case 
estimation. ConClusions: In a scenario of comparable efficacy between both PIs, 
the resources wasted on TF acquire a great importance in selecting the least costly of 
the two alternatives. Based on CUPIC study reported data, the average PI cost/patient 
who failed treatment was significantly higher in TLV patients than in BOC patients.
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